Based on the study of Roselk et al. [33] In 2023, 290 cases of lung neuroendocrine neoplasms (LNENs) found that ProGRP Is an effective blomarker for diagnosis, with median levels significantly higher In LNEN patients (136.4 pg/mL) compared to controls (6.5 pg/mL). This evidence concerns the gene GRP and lung neuroendocrine neoplasm.